Literature DB >> 12691643

The rational use of diuretics in heart failure.

Susan L Ravnan1, Prakash C Deedwania.   

Abstract

Congestive heart failure is a progressive hemodynamic disorder associated with significant morbidity and mortality. Concomitant renal dysfunction is frequently seen in patients with heart failure, and can compromise fluid regulation, leading to acute decompensation, and increased morbidity and mortality. Diuretic therapy has been the mainstay for treatment of congestive symptoms, despite documented mortality benefits. Misuse or overuse of diuretics can have negative consequences in heart failure, and optimizing diuretic efficiency may improve outcomes. In addition, new agents targeting elevated neuropeptides may prove to be beneficial in regulating fluid status and optimizing renal function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691643     DOI: 10.1007/s11886-003-0055-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  43 in total

1.  Mechanism of impaired natriuretic response to furosemide during prolonged therapy.

Authors:  N R Loon; C S Wilcox; R J Unwin
Journal:  Kidney Int       Date:  1989-10       Impact factor: 10.612

2.  BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.

Authors:  Stephen S Gottlieb; D Craig Brater; Ignatius Thomas; Edward Havranek; Robert Bourge; Steven Goldman; Farere Dyer; Miguel Gomez; Donald Bennett; Barry Ticho; Evan Beckman; William T Abraham
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

3.  Aggressive diuresis for severe heart failure in the elderly.

Authors:  P A Howard; M I Dunn
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

Review 4.  Pathophysiology and clinical spectrum of acute congestive heart failure.

Authors:  M Shah; V Ali; S Lamba; W T Abraham
Journal:  Rev Cardiovasc Med       Date:  2001       Impact factor: 2.930

Review 5.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance.

Authors:  D H Ellison
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

6.  Role of duration of diuretic effect in preventing sodium retention.

Authors:  J A Ferguson; K J Sundblad; P K Becker; J C Gorski; D W Rudy; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

7.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

8.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry).

Authors:  Giovanni Pulignano; Donatella Del Sindaco; Luigi Tavazzi; Donata Lucci; Marco Gorini; Francesco Leggio; Maurizio Porcu; Marino Scherillo; Cristina Opasich; Andrea Di Lenarda; Michele Senni; Aldo Pietro Maggioni
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

Review 9.  Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

10.  Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance.

Authors:  J J van Meyel; P Smits; T Dormans; P G Gerlag; F G Russel; F W Gribnau
Journal:  J Intern Med       Date:  1994-04       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.